Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 551–560 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 551
- Medicine slug
- eslicarbazepine
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 10
- Source count
- 10
- Agreement rate
- 1
- Recorded readings
1 to 4 hours
- Numeric value
- 1
- Unit
- hours
- Source records
- 10
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 10 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22f29752-614f-caaf-b595-9deae8a3e3ff (opens source in a new tab)
Eslicarbazepine label
Version not recorded · Effective date not recorded
Peak plasma concentrations (C max ) of eslicarbazepine are attained at 1 to 4 hours post-dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d279e461-2611-4f5c-938d-5d117612894f (opens source in a new tab)
Eslicarbazepine label
Version not recorded · Effective date not recorded
Peak plasma concentrations (Cmax) of eslicarbazepine are attained at 1 to 4 hours post-dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2067fb77-9657-44da-b430-02e8a4efacb5 (opens source in a new tab)
Eslicarbazepine label
Version not recorded · Effective date not recorded
Peak plasma concentrations (C max ) of eslicarbazepine are attained at 1 to 4 hours post-dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:28efe9d2-9d7b-4a7c-8458-098456d06604 (opens source in a new tab)
Eslicarbazepine label
Version not recorded · Effective date not recorded
Peak plasma concentrations (C max ) of eslicarbazepine are attained at 1 to 4 hours post-dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:999b341f-fe13-4dd9-bb95-9b0d6a817c4c (opens source in a new tab)
Eslicarbazepine label
Version not recorded · Effective date not recorded
Peak plasma concentrations (C max ) of eslicarbazepine are attained at 1 to 4 hours post-dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6200ae2e-ac4e-41b6-a1c3-0ea00703d7e3 (opens source in a new tab)
Eslicarbazepine label
Version not recorded · Effective date not recorded
Peak plasma concentrations (C max ) of eslicarbazepine are attained at 1 to 4 hours post-dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a3b3e50-6590-0040-e063-6294a90a84c1 (opens source in a new tab)
Eslicarbazepine label
Version not recorded · Effective date not recorded
Peak plasma concentrations (C max ) of eslicarbazepine are attained at 1 to 4 hours post-dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3d0c9554-eaeb-4694-8089-00133fcadce3 (opens source in a new tab)
Eslicarbazepine label
Version not recorded · Effective date not recorded
Peak plasma concentrations (Cmax) of eslicarbazepine are attained at 1-4 hours post-dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22d08671-ac0d-4e3d-8195-929bbb021125 (opens source in a new tab)
Eslicarbazepine label
Version not recorded · Effective date not recorded
Peak plasma concentrations (C max ) of eslicarbazepine are attained at 1-4 hours post-dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:190fccbc-da3f-b175-ac02-f2c4307a15c3 (opens source in a new tab)
Eslicarbazepine label
Version not recorded · Effective date not recorded
Peak plasma concentrations (C max ) of eslicarbazepine are attained at 1 to 4 hours post-dose.
Projected row 552
- Medicine slug
- eslicarbazepine
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 10
- Source count
- 10
- Agreement rate
- 1
- Recorded readings
61 L
- Numeric value
- 61
- Unit
- L
- Source records
- 10
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 10 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22f29752-614f-caaf-b595-9deae8a3e3ff (opens source in a new tab)
Eslicarbazepine label
Version not recorded · Effective date not recorded
The apparent volume of distribution of eslicarbazepine is 61 L for body weight of 70 kg based on population PK analysis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d279e461-2611-4f5c-938d-5d117612894f (opens source in a new tab)
Eslicarbazepine label
Version not recorded · Effective date not recorded
The apparent volume of distribution of eslicarbazepine is 61 L for body weight of 70 kg based on population PK analysis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2067fb77-9657-44da-b430-02e8a4efacb5 (opens source in a new tab)
Eslicarbazepine label
Version not recorded · Effective date not recorded
The apparent volume of distribution of eslicarbazepine is 61 L for body weight of 70 kg based on population PK analysis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:28efe9d2-9d7b-4a7c-8458-098456d06604 (opens source in a new tab)
Eslicarbazepine label
Version not recorded · Effective date not recorded
The apparent volume of distribution of eslicarbazepine is 61 L for body weight of 70 kg based on population PK analysis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:999b341f-fe13-4dd9-bb95-9b0d6a817c4c (opens source in a new tab)
Eslicarbazepine label
Version not recorded · Effective date not recorded
The apparent volume of distribution of eslicarbazepine is 61 L for body weight of 70 kg based on population PK analysis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6200ae2e-ac4e-41b6-a1c3-0ea00703d7e3 (opens source in a new tab)
Eslicarbazepine label
Version not recorded · Effective date not recorded
The apparent volume of distribution of eslicarbazepine is 61 L for body weight of 70 kg based on population PK analysis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a3b3e50-6590-0040-e063-6294a90a84c1 (opens source in a new tab)
Eslicarbazepine label
Version not recorded · Effective date not recorded
The apparent volume of distribution of eslicarbazepine is 61 L for body weight of 70 kg based on population PK analysis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3d0c9554-eaeb-4694-8089-00133fcadce3 (opens source in a new tab)
Eslicarbazepine label
Version not recorded · Effective date not recorded
The apparent volume of distribution of eslicarbazepine is 61 L for body weight of 70 kg based on population PK analysis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22d08671-ac0d-4e3d-8195-929bbb021125 (opens source in a new tab)
Eslicarbazepine label
Version not recorded · Effective date not recorded
The apparent volume of distribution of eslicarbazepine is 61 L for body weight of 70 kg based on population PK analysis.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:190fccbc-da3f-b175-ac02-f2c4307a15c3 (opens source in a new tab)
Eslicarbazepine label
Version not recorded · Effective date not recorded
The apparent volume of distribution of eslicarbazepine is 61 L for body weight of 70 kg based on population PK analysis.
Projected row 553
- Medicine slug
- esmolol
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 21
- Source count
- 21
- Agreement rate
- 1
- Recorded readings
3.7 hours
- Numeric value
- 3.7
- Unit
- hours
- Source records
- 21
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 21 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9a3e69ab-3ffe-33af-e053-2a95a90a6524 (opens source in a new tab)
Esmolol label
Version not recorded · Effective date not recorded
The acid metabolite has an elimination half-life of about 3.7 hours and is excreted in the urine with a clearance approximately equivalent to the glomerular filtration rate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6bb9921c-a0f9-309f-e053-2a91aa0a1e5e (opens source in a new tab)
Esmolol label
Version not recorded · Effective date not recorded
The acid metabolite has an elimination half-life of about 3.7 hours and is excreted in the urine with a clearance approximately equivalent to the glomerular filtration rate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:017023a9-00f0-4284-861f-a3634d4fdb17 (opens source in a new tab)
Esmolol label
Version not recorded · Effective date not recorded
The acid metabolite has an elimination half-life of about 3.7 hours and is excreted in the urine with a clearance approximately equivalent to the glomerular filtration rate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:94f069f9-dd52-4a69-a103-ebdb4294f088 (opens source in a new tab)
Esmolol label
Version not recorded · Effective date not recorded
The acid metabolite has an elimination half-life of about 3.7 hours and is excreted in the urine with a clearance approximately equivalent to the glomerular filtration rate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:993df35b-0006-4892-e053-2a95a90a0dba (opens source in a new tab)
Esmolol label
Version not recorded · Effective date not recorded
The acid metabolite has an elimination half-life of about 3.7 hours and is excreted in the urine with a clearance approximately equivalent to the glomerular filtration rate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9a52d2fd-e551-f8f1-e053-2995a90a6c09 (opens source in a new tab)
Esmolol label
Version not recorded · Effective date not recorded
The acid metabolite has an elimination half-life of about 3.7 hours and is excreted in the urine with a clearance approximately equivalent to the glomerular filtration rate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c593cdb-cdfe-4492-8862-9b05116aa25e (opens source in a new tab)
Esmolol label
Version not recorded · Effective date not recorded
The acid metabolite has an elimination half-life of about 3.7 hours and is excreted in the urine with a clearance approximately equivalent to the glomerular filtration rate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c1e3a64-0ef0-4071-ad6f-63ff8789b198 (opens source in a new tab)
Esmolol label
Version not recorded · Effective date not recorded
The acid metabolite has an elimination half-life of about 3.7 hours and is excreted in the urine with a clearance approximately equivalent to the glomerular filtration rate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:789730fa-eaca-4986-e053-2a91aa0a5339 (opens source in a new tab)
Esmolol label
Version not recorded · Effective date not recorded
The acid metabolite has an elimination half-life of about 3.7 hours and is excreted in the urine with a clearance approximately equivalent to the glomerular filtration rate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38a8b23a-fca8-45f4-a09a-9c8b21f522cd (opens source in a new tab)
Esmolol label
Version not recorded · Effective date not recorded
The acid metabolite has an elimination half-life of about 3.7 hours and is excreted in the urine with a clearance approximately equivalent tot he glomerular filtration rate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:220a07b8-5c68-41a3-8705-fd91f14c50b4 (opens source in a new tab)
Esmolol label
Version not recorded · Effective date not recorded
The acid metabolite has an elimination half-life of about 3.7 hours and is excreted in the urine with a clearance approximately equivalent to the glomerular filtration rate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0a56c07-8f0f-4499-8d00-f13a966bf988 (opens source in a new tab)
Esmolol label
Version not recorded · Effective date not recorded
The acid metabolite has an elimination half-life of about 3.7 hours and is excreted in the urine with a clearance approximately equivalent to the glomerular filtration rate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:60b10020-f802-4fef-a487-0f11eca246c5 (opens source in a new tab)
Esmolol label
Version not recorded · Effective date not recorded
The acid metabolite has an elimination half-life of about 3.7 hours and is excreted in the urine with a clearance approximately equivalent to the glomerular filtration rate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f5707f2-a8a7-4a5f-b846-64585b5e3f9f (opens source in a new tab)
Esmolol label
Version not recorded · Effective date not recorded
The acid metabolite has an elimination half-life of about 3.7 hours and is excreted in the urine with a clearance approximately equivalent to the glomerular filtration rate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f12fb0fd-fa05-49fc-b5e3-a2050b816ef2 (opens source in a new tab)
Esmolol label
Version not recorded · Effective date not recorded
The acid metabolite has an elimination half-life of about 3.7 hours and is excreted in the urine with a clearance approximately equivalent to the glomerular filtration rate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:519cc19c-e2b6-4984-bfad-45276d4cf0e6 (opens source in a new tab)
Esmolol label
Version not recorded · Effective date not recorded
The acid metabolite has an elimination half-life of about 3.7 hours and is excreted in the urine with a clearance approximately equivalent to the glomerular filtration rate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac22475d-2d78-469f-9435-b403ac4ee380 (opens source in a new tab)
Esmolol label
Version not recorded · Effective date not recorded
The acid metabolite has an elimination half-life of about 3.7 hours and is excreted in the urine with a clearance approximately equivalent to the glomerular filtration rate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fdc9cea8-0eb4-4930-9e1c-d44bfa9346d2 (opens source in a new tab)
Esmolol label
Version not recorded · Effective date not recorded
The acid metabolite has an elimination half-life of about 3.7 hours and is excreted in the urine with a clearance approximately equivalent to the glomerular filtration rate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6bdd5315-75ce-1537-e053-2991aa0a6549 (opens source in a new tab)
Esmolol label
Version not recorded · Effective date not recorded
The acid metabolite has an elimination half-life of about 3.7 hours and is excreted in the urine with a clearance approximately equivalent to the glomerular filtration rate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3853a26d-782d-f4e7-e063-6294a90a6e47 (opens source in a new tab)
Esmolol label
Version not recorded · Effective date not recorded
The acid metabolite has an elimination half-life of about 3.7 hours and is excreted in the urine with a clearance approximately equivalent to the glomerular filtration rate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:595cc3d5-1306-4828-aefa-5595219ffd62 (opens source in a new tab)
Esmolol label
Version not recorded · Effective date not recorded
The acid metabolite has an elimination half-life of about 3.7 hours and is excreted in the urine with a clearance approximately equivalent to the glomerular filtration rate.
Projected row 554
- Medicine slug
- esmolol
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 21
- Source count
- 21
- Agreement rate
- 1
- Recorded readings
10%
- Numeric value
- 10
- Unit
- %
- Source records
- 21
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 21 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9a3e69ab-3ffe-33af-e053-2a95a90a6524 (opens source in a new tab)
Esmolol label
Version not recorded · Effective date not recorded
BREVIBLOC injection has been shown to be 55% bound to human plasma protein, while the acid metabolite is only 10% bound.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6bb9921c-a0f9-309f-e053-2a91aa0a1e5e (opens source in a new tab)
Esmolol label
Version not recorded · Effective date not recorded
Esmolol hydrochloride has been shown to be 55% bound to human plasma protein, while the acid metabolite is only 10% bound. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Esmolol hydrochloride is a beta 1 -selective (cardioselective) adrenergic receptor blocking agent with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane stabilizing activity
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:017023a9-00f0-4284-861f-a3634d4fdb17 (opens source in a new tab)
Esmolol label
Version not recorded · Effective date not recorded
Esmolol hydrochloride injection has been shown to be 55% bound to human plasma protein, while the acid metabolite is only 10% bound. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Esmolol hydrochloride injection is a beta 1 -selective (cardioselective) adrenergic receptor blocking agent with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane s
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:94f069f9-dd52-4a69-a103-ebdb4294f088 (opens source in a new tab)
Esmolol label
Version not recorded · Effective date not recorded
Esmolol hydrochloride injection has been shown to be 55% bound to human plasma protein, while the acid metabolite is only 10% bound. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Esmolol hydrochloride injection is a beta 1 -selective (cardioselective) adrenergic receptor blocking agent with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane s
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:993df35b-0006-4892-e053-2a95a90a0dba (opens source in a new tab)
Esmolol label
Version not recorded · Effective date not recorded
Esmolol hydrochloride has been shown to be 55% bound to human plasma protein, while the acid metabolite is only 10% bound.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9a52d2fd-e551-f8f1-e053-2995a90a6c09 (opens source in a new tab)
Esmolol label
Version not recorded · Effective date not recorded
Esmolol hydrochloride has been shown to be 55% bound to human plasma protein, while the acid metabolite is only 10% bound.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c593cdb-cdfe-4492-8862-9b05116aa25e (opens source in a new tab)
Esmolol label
Version not recorded · Effective date not recorded
BREVIBLOC injection has been shown to be 55% bound to human plasma protein, while the acid metabolite is only 10% bound. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action BREVIBLOC (Esmolol Hydrochloride) injection is a beta 1 -selective (cardioselective) adrenergic receptor blocking agent with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane s
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c1e3a64-0ef0-4071-ad6f-63ff8789b198 (opens source in a new tab)
Esmolol label
Version not recorded · Effective date not recorded
Esmolol hydrochloride injection has been shown to be 55% bound to human plasma protein, while the acid metabolite is only 10% bound.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:789730fa-eaca-4986-e053-2a91aa0a5339 (opens source in a new tab)
Esmolol label
Version not recorded · Effective date not recorded
Esmolol hydrochloride has been shown to be 55% bound to human plasma protein, while the acid metabolite is only 10% bound.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38a8b23a-fca8-45f4-a09a-9c8b21f522cd (opens source in a new tab)
Esmolol label
Version not recorded · Effective date not recorded
BREVIBLOC has been shown to be 55% bound to human plasma protein, while the acid metabolite is only 10% bound. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action BREVIBLOC (Esmolol Hydrochloride) is a beta1-selective (cardioselective) adrenergic receptor blocking agent with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane stabilizing activity at
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:220a07b8-5c68-41a3-8705-fd91f14c50b4 (opens source in a new tab)
Esmolol label
Version not recorded · Effective date not recorded
BREVIBLOC injection has been shown to be 55% bound to human plasma protein, while the acid metabolite is only 10% bound. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action BREVIBLOC (Esmolol Hydrochloride) injection is a beta 1 -selective (cardioselective) adrenergic receptor blocking agent with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane s
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f0a56c07-8f0f-4499-8d00-f13a966bf988 (opens source in a new tab)
Esmolol label
Version not recorded · Effective date not recorded
Esmolol hydrochloride injection has been shown to be 55% bound to human plasma protein, while the acid metabolite is only 10% bound. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Esmolol hydrochloride injection is a beta 1 -selective (cardioselective) adrenergic receptor blocking agent with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane s
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:60b10020-f802-4fef-a487-0f11eca246c5 (opens source in a new tab)
Esmolol label
Version not recorded · Effective date not recorded
Esmolol hydrochloride has been shown to be 55% bound to human plasma protein, while the acid metabolite is only 10% bound.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1f5707f2-a8a7-4a5f-b846-64585b5e3f9f (opens source in a new tab)
Esmolol label
Version not recorded · Effective date not recorded
Esmolol hydrochloride has been shown to be 55% bound to human plasma protein, while the acid metabolite is only 10% bound. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Esmolol hydrochloride is a beta 1 -selective (cardioselective) adrenergic receptor blocking agent with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane stabilizing activity
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f12fb0fd-fa05-49fc-b5e3-a2050b816ef2 (opens source in a new tab)
Esmolol label
Version not recorded · Effective date not recorded
Esmolol hydrochloride has been shown to be 55% bound to human plasma protein, while the acid metabolite is only 10% bound. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Esmolol hydrochloride is a beta 1 -selective (cardioselective) adrenergic receptor blocking agent with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane stabilizing activity
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:519cc19c-e2b6-4984-bfad-45276d4cf0e6 (opens source in a new tab)
Esmolol label
Version not recorded · Effective date not recorded
Esmolol hydrochloride has been shown to be 55% bound to human plasma protein, while the acid metabolite is only 10% bound.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac22475d-2d78-469f-9435-b403ac4ee380 (opens source in a new tab)
Esmolol label
Version not recorded · Effective date not recorded
Esmolol hydrochloride has been shown to be 55% bound to human plasma protein, while the acid metabolite is only 10% bound. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Esmolol hydrochloride is a beta 1 -selective (cardioselective) adrenergic receptor blocking agent with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane stabilizing activity
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fdc9cea8-0eb4-4930-9e1c-d44bfa9346d2 (opens source in a new tab)
Esmolol label
Version not recorded · Effective date not recorded
Esmolol hydrochloride has been shown to be 55% bound to human plasma protein, while the acid metabolite is only 10% bound. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Esmolol hydrochloride is a beta 1 -selective (cardioselective) adrenergic receptor blocking agent with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane stabilizing activity
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6bdd5315-75ce-1537-e053-2991aa0a6549 (opens source in a new tab)
Esmolol label
Version not recorded · Effective date not recorded
Esmolol hydrochloride has been shown to be 55% bound to human plasma protein, while the acid metabolite is only 10% bound. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Esmolol hydrochloride is a beta 1 -selective (cardioselective) adrenergic receptor blocking agent with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane stabilizing activity
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3853a26d-782d-f4e7-e063-6294a90a6e47 (opens source in a new tab)
Esmolol label
Version not recorded · Effective date not recorded
Esmolol hydrochloride has been shown to be 55% bound to human plasma protein, while the acid metabolite is only 10% bound. 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Esmolol hydrochloride is a beta 1 -selective (cardioselective) adrenergic receptor blocking agent with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane stabilizing activity
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:595cc3d5-1306-4828-aefa-5595219ffd62 (opens source in a new tab)
Esmolol label
Version not recorded · Effective date not recorded
BREVIBLOC injection has been shown to be 55% bound to human plasma protein, while the acid metabolite is only 10% bound.
Projected row 555
- Medicine slug
- esomeprazole
- Compared field
- bioavailability
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 41
- Source count
- 4
- Agreement rate
- 0.75
- Recorded readings
10%
- Numeric value
- 10
- Unit
- %
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9354958c-e997-41c8-8605-23f0a58993c0 (opens source in a new tab)
Esomeprazole label
Version not recorded · Effective date not recorded
Digoxin Concomitant administration of omeprazole 20 mg once daily and digoxin in healthy subjects increased the bioavailability of digoxin by 10% (30% in two subjects) [see Drug Interactions (7) ].
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:45a15ba2-2aae-4edc-beaa-4a2357d87f32 (opens source in a new tab)
Esomeprazole label
Version not recorded · Effective date not recorded
Digoxin Concomitant administration of omeprazole 20 mg once daily and digoxin in healthy subjects increased the bioavailability of digoxin by 10% (30% in two subjects) [see Drug Interactions (7) ] .
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:23395673-116d-4a8e-b0ce-59f9ca5b3daf (opens source in a new tab)
Esomeprazole label
Version not recorded · Effective date not recorded
Digoxin Concomitant administration of omeprazole 20 mg once daily and digoxin in healthy subjects increased the bioavailability of digoxin by 10% (30% in two subjects) [see Drug Interactions (7) ] .
90%
- Numeric value
- 90
- Unit
- %
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d68c9247-91c7-4e0f-adc4-2cfa7446580f (opens source in a new tab)
Esomeprazole label
Version not recorded · Effective date not recorded
At repeated once-daily dosing with 40 mg, the systemic bioavailability is approximately 90% compared to 64% after a single dose of 40 mg.
Projected row 556
- Medicine slug
- esomeprazole
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 41
- Source count
- 4
- Agreement rate
- 1
- Recorded readings
16 L
- Numeric value
- 16
- Unit
- L
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9354958c-e997-41c8-8605-23f0a58993c0 (opens source in a new tab)
Esomeprazole label
Version not recorded · Effective date not recorded
The apparent volume of distribution at steady state in healthy subjects is approximately 16 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:45a15ba2-2aae-4edc-beaa-4a2357d87f32 (opens source in a new tab)
Esomeprazole label
Version not recorded · Effective date not recorded
The apparent volume of distribution at steady state in healthy subjects is approximately 16 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:23395673-116d-4a8e-b0ce-59f9ca5b3daf (opens source in a new tab)
Esomeprazole label
Version not recorded · Effective date not recorded
The apparent volume of distribution at steady state in healthy subjects is approximately 16 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d68c9247-91c7-4e0f-adc4-2cfa7446580f (opens source in a new tab)
Esomeprazole label
Version not recorded · Effective date not recorded
The apparent volume of distribution at steady state in healthy subjects is approximately 16 L.
Projected row 557
- Medicine slug
- estazolam
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 3
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
10 to 24 hours
- Numeric value
- 10
- Unit
- hours
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a1e3b4bf-22e9-430a-a768-4d86ae886c9e (opens source in a new tab)
Estazolam label
Version not recorded · Effective date not recorded
Elimination The range of estimates for the mean elimination half-life of estazolam varied from 10 to 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1c77eb1-9cba-4e89-a03f-9fb797add4f0 (opens source in a new tab)
Estazolam label
Version not recorded · Effective date not recorded
Elimination The range of estimates for the mean elimination half-life of estazolam varied from 10 to 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2f349a44-6d04-01d1-c8b7-12254aead77d (opens source in a new tab)
Estazolam label
Version not recorded · Effective date not recorded
Elimination The range of estimates for the mean elimination half-life of estazolam varied from 10 to 24 hours.
Projected row 558
- Medicine slug
- estradiol
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 134
- Source count
- 21
- Agreement rate
- 0.47619
- Recorded readings
10 hours
- Numeric value
- 10
- Unit
- hours
- Source records
- 10
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 10 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e927450-3f02-4d2f-9235-a255357e8d93 (opens source in a new tab)
Estradiol label
Version not recorded · Effective date not recorded
The apparent terminal half-life for estradiol was about 10 hours following administration of estradiol gel.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6a4e82a4-d980-4c04-9e33-9444a292728a (opens source in a new tab)
Estradiol label
Version not recorded · Effective date not recorded
The apparent terminal half-life for estradiol was about 10 hours following administration of estradiol gel.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ac905b3-904c-4285-97ed-e787d006c7dd (opens source in a new tab)
Estradiol label
Version not recorded · Effective date not recorded
The apparent terminal half-life for estradiol was about 10 hours following administration of estradiol gel.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eab9a629-b3d4-4faf-bce4-656fe3b46d38 (opens source in a new tab)
Estradiol label
Version not recorded · Effective date not recorded
The apparent terminal half-life for estradiol was about 10 hours following administration of estradiol gel.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e84ad638-6768-41aa-b2b8-e2514ef63881 (opens source in a new tab)
Estradiol label
Version not recorded · Effective date not recorded
The apparent terminal half-life for estradiol was about 10 hours following administration of estradiol gel.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0c8a07a4-5762-eaf4-e063-6394a90a54ff (opens source in a new tab)
Estradiol label
Version not recorded · Effective date not recorded
The apparent terminal half-life for estradiol was about 10 hours following administration of estradiol gel.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59e610dc-883e-4f07-9ec6-a5841b0bf9fb (opens source in a new tab)
Estradiol label
Version not recorded · Effective date not recorded
The apparent terminal half-life for estradiol was about 10 hours following administration of Divigel.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff28c624-906d-459c-8b8c-27cb1a664e12 (opens source in a new tab)
Estradiol label
Version not recorded · Effective date not recorded
The apparent terminal half-life for estradiol was about 10 hours following administration of estradiol gel.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d4a3606f-83b2-45df-bc77-faebfa796f9a (opens source in a new tab)
Estradiol label
Version not recorded · Effective date not recorded
The apparent terminal half-life for estradiol was about 10 hours following administration of estradiol gel 0.1%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e6bf2abc-71ae-4e79-a37b-164c98ba746a (opens source in a new tab)
Estradiol label
Version not recorded · Effective date not recorded
The apparent terminal half-life for estradiol was about 10 hours following administration of estradiol gel.
5.9 to 7.7 hours
- Numeric value
- 5.9
- Unit
- hours
- Source records
- 6
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 6 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:75fc6d3a-49b6-47ad-b704-410692010d3a (opens source in a new tab)
Estradiol label
Version not recorded · Effective date not recorded
The half-life values calculated after dosing with DOTTI ranged from 5.9 to 7.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:779751dc-243a-4dc2-ae67-3669f196b205 (opens source in a new tab)
Estradiol label
Version not recorded · Effective date not recorded
The half-life values calculated after dosing with DOTTI ranged from 5.9 to 7.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:99b889a0-6200-4727-97d3-f5a0b7814e1b (opens source in a new tab)
Estradiol label
Version not recorded · Effective date not recorded
The half-life values calculated after dosing with DOTTI ranged from 5.9 to 7.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53016d30-6b5f-49da-ac16-85ef415a5805 (opens source in a new tab)
Estradiol label
Version not recorded · Effective date not recorded
The half-life values calculated after dosing with DOTTI ranged from 5.9 to 7.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f419192a-eb95-4087-9fe0-0eea639ef51b (opens source in a new tab)
Estradiol label
Version not recorded · Effective date not recorded
The half-life values calculated after dosing with DOTTI ranged from 5.9 to 7.7 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b119df4a-c514-4804-b1a8-b09c6058e80d (opens source in a new tab)
Estradiol label
Version not recorded · Effective date not recorded
The half-life values calculated after dosing with DOTTI ranged from 5.9 to 7.7 hours.
36 hours
- Numeric value
- 36
- Unit
- hours
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:54f108d6-ddd2-4276-8508-2c8e16a65fb2 (opens source in a new tab)
Estradiol label
Version not recorded · Effective date not recorded
The apparent terminal exponential half-life for estradiol was about 36 hours following administration of 1.25 g estradiol gel.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67e8665c-5331-423c-99fd-546ab6cccb07 (opens source in a new tab)
Estradiol label
Version not recorded · Effective date not recorded
The apparent terminal exponential half-life for estradiol was about 36 hours following administration of 1.25 g estradiol gel.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3518120e-cc44-4d70-8a20-0ef2dce9a3c6 (opens source in a new tab)
Estradiol label
Version not recorded · Effective date not recorded
The apparent terminal exponential half-life for estradiol was about 36 hours following administration of 1.25 g estradiol gel.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:762ac371-bb8b-47e7-b48f-e80d452c9dd4 (opens source in a new tab)
Estradiol label
Version not recorded · Effective date not recorded
The apparent terminal exponential half-life for estradiol was about 36 hours following administration of 1.25 g EstroGel.
21 to 26 hours
- Numeric value
- 21
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7aaa97f9-a9d1-c815-e053-2991aa0afb9e (opens source in a new tab)
Estradiol label
Version not recorded · Effective date not recorded
The estradiol apparent elimination half-life value is 21 to 26 hours.
Projected row 559
- Medicine slug
- estradiol
- Compared field
- tMax
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 134
- Source count
- 2
- Agreement rate
- 0.5
- Recorded readings
0.5 to 1 hour
- Numeric value
- 0.5
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:110b9865-5a07-4d45-b560-e89947f12600 (opens source in a new tab)
Estradiol label
Version not recorded · Effective date not recorded
The time to attain peak serum estradiol levels (T max ) was 0.5 to 1 hour.
1 hour
- Numeric value
- 1
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7aaa97f9-a9d1-c815-e053-2991aa0afb9e (opens source in a new tab)
Estradiol label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Estradiol acetate is hydrolyzed to estradiol which is absorbed through the vaginal mucosa as evidenced by the mean time to maximum concentration (t max ) for estradiol of about 1 hour (range 0.25 to 1.5 hrs).
Projected row 560
- Medicine slug
- eszopiclone
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 63
- Source count
- 63
- Agreement rate
- 1
- Recorded readings
6 hours
- Numeric value
- 6
- Unit
- hours
- Source records
- 63
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 63 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6022b2f-9b43-40cc-91c7-c224b209efab (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d301b0cf-1492-4be9-83a0-1b64c8fa3b72 (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d1baa5ba-73ac-462b-a728-217d5992674a (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af86ebdb-e47b-706a-e053-2995a90ad51c (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (tmax) of approximately 1 hour and a terminal-phase elimination half-life (t1/2) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:52ab8ee9-a04d-4e27-b0f4-eb050f144715 (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2435e2f1-bc52-488f-80e9-f1758e354aae (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c4ff1d6a-918e-c046-e053-2a95a90a9c9b (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:10175591-c1b4-461a-830e-8df982d0d2bf (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:edc03482-b013-448a-8cd9-2a17bd6d15e9 (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bfa767ce-340b-4d3a-a9c7-0043b6d7ff6e (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7df922bc-5750-4259-906f-64f960c38d5f (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac996f97-fd92-44f8-8bb5-478a81ffb33d (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2f4fa6e8-be82-4fb5-9a11-9ba8f557c027 (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1582ba77-a4e3-464f-876b-28cc7e41e8f1 (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ec6ac172-509e-403a-aa0d-4c60010a0035 (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (tmax) of approximately 1 hour and a terminal-phase elimination half-life (t1/2) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e32746a8-6440-4b0a-a445-4467cf0329d5 (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd7e4bab-8e25-4788-89e4-6b391f9596fe (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:61fd4655-060f-4393-a610-019d8b127058 (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:838559f7-4b69-4831-bf50-ab37c6c24c2b (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c8ae09eb-4c9b-4560-e053-2995a90a02b1 (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (tmax) of approximately 1 hour and a terminal-phase elimination half-life (t1/2) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b8a09c6-0702-43a7-b47f-a36cd00b7584 (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8bb1965e-7845-4c5b-b021-38e251303d68 (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9bbf260f-3090-46b5-b3ef-81174697f166 (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af86b753-d2ee-9b5f-e053-2a95a90ad23d (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (tmax) of approximately 1 hour and a terminal-phase elimination half-life (t1/2) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:be25bb4e-d84f-4396-a78f-a668a207cf2d (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e261bf7f-1b89-4393-8c48-4e72fc29192f (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:00fc3250-3e29-4a4b-ac0c-74910659337c (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:abe3a610-a25d-4b52-8537-c87e8ba3104a (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3821f4b7-a3c8-4920-ba80-18aa96532c09 (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c24ec179-f869-746f-e053-2995a90aa1ff (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9dfe774a-2c7a-4e10-bedd-cde64ad28676 (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af86fca8-571a-0cac-e053-2a95a90ae402 (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (tmax) of approximately 1 hour and a terminal-phase elimination half-life (t1/2) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9a891ab1-675f-498e-a21e-05964307d2dd (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb972d36-4b2c-45ae-8504-3a16d352dd8b (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57a8450c-59ee-4c96-bef4-308fa7b97d1e (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4832cfbf-a540-46af-bb7d-3ba8e6bc783e (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e04d4f8b-c9a1-4dc9-aac4-2e6376cd9a0c (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7832f554-2b82-4ef2-b1ef-266179f271d3 (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5451be60-1315-4152-ad13-412e86903c8a (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:12593790-e72f-45b1-8895-987cdd075134 (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f18cc76f-82aa-4ad7-b8ce-5737733ee104 (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0b363b90-93dc-1fc1-0501-d140dfc762c7 (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4f272eb-02e3-415a-e053-2a95a90a428f (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (tmax) of approximately 1 hour and a terminal-phase elimination half-life (t1/2) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7bd3e3c-26e9-07e7-e053-2995a90a9ca5 (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (tmax) of approximately 1 hour and a terminal-phase elimination half-life (t1/2) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:923cc646-f22a-4a26-88f7-a19fce016321 (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:584dc66c-063a-4552-a056-74b811e2bc80 (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:486b760b-7fea-306b-e054-00144ff8d46c (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (tmax) of approximately 1 hour and a terminal-phase elimination half-life (t1/2) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0102ea59-77b1-4e74-83ec-1d205563b55f (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9460be93-cd53-4429-a4d9-2f04e3835168 (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af863d89-25db-2893-e053-2a95a90a704c (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (tmax) of approximately 1 hour and a terminal-phase elimination half-life (t1/2) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b39dc64d-adc9-742e-e053-2a95a90ad18b (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (tmax) of approximately 1 hour and a terminal-phase elimination half-life (t1/2) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af869866-0a11-1a05-e053-2a95a90acdb8 (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (tmax) of approximately 1 hour and a terminal-phase elimination half-life (t1/2) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b5b4fbb-9b86-46c6-9508-37d3d9806dec (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:53fcee89-027a-13e5-e054-00144ff8d46c (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5469cc59-78f9-447a-9c33-12553bb4073d (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bad8fe65-73c1-4542-8050-720af889905a (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7068c455-691e-4c56-9857-b7b4e13f4784 (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fef87d8d-f375-4b00-8765-957ef076bf1a (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1baa56e5-34d5-c8a1-e063-6394a90ae6c7 (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:39b96725-2a01-4d9f-a56d-af7491b3b601 (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:024f833e-c20c-46a2-971b-3f2a716b1678 (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af86fca8-571e-0cac-e053-2a95a90ae402 (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (tmax) of approximately 1 hour and a terminal-phase elimination half-life (t1/2) of approximately 6 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:45558f0a-83f1-49b9-ab18-f436c0be9677 (opens source in a new tab)
Eszopiclone label
Version not recorded · Effective date not recorded
Eszopiclone is rapidly absorbed, with a time to peak concentration (t max ) of approximately 1 hour and a terminal-phase elimination half-life (t 1/2 ) of approximately 6 hours.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=550Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.